Trademark: 79226526
Word
PRIAVOID
Status Date
Tuesday, October 16, 2018
Registration Number
5582971
Registration Date
Tuesday, October 16, 2018
Filing Date
Tuesday, June 20, 2017
Published for Opposition
Tuesday, July 31, 2018
5 Pharmaceuticals for the prevention and treatment of allergies and for the abatement of burns; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceuticals, namely, anti-infectives, immunostimulants; implantable pharmaceuticals namely, biological tissues grafts; serotherapeutic pharmaceuticals for treatment of meningitis and respiratory disorders; pharmaceutical drugs for treatment of Alzheimer's and dementia; medicated throat sprays; medicine for dental purpose; medicine for veterinary purpose, namely, bacteriostats; medicine for intestinal diseases; pharmaceutical preparations for human purposes, namely, for treatment of Alzheimer's and dementia; pharmaceuticals for the treatment of the autonomic nervous system; pharmaceuticals for the treatment of gastrointestinal diseases; pharmaceutical compounds and products for treatment of Alzheimer's and dementia; chemical and pharmaceutical products and preparations for medical purposes, namely, medical diagnostic reagents; antiepileptic pharmaceutical preparations; pharmaceutical compounds and substances for treatment of Alzheimer's and dementia; chemical compounds for pharmaceutical purpose, namely, for the diagnosis of pregnancy; pharmaceutical agents for metabolism; pharmaceutical agents for treatment of the intestines; pharmaceutical compounds for human use, namely, menstrual symptom treatment preparations; synthetic peptides for pharmaceutical purpose for the prevention and treatment of flu; pharmaceutical agents and compounds for the peripheral nervous system; pharmaceutical products for the treatment of infections; pharmaceutical products for the treatment of hyperlipidemias; crystals for therapeutical purpose being pharmaceutical products, namely, mineral preparations; pharmaceutical compounds for the prevention and treatment of metabolic disorder; pharmaceutical compounds for the treatment of kidney diseases; pharmaceutical compounds for the prevention and treatment of metabolic diseases; chemicals for pharmaceutical use, namely, chemical preparations for the diagnosis of pregnancy; pharmaceutical compounds for the treatment of a chemical imbalance; pharmaceutical preparations for the central nervous system; pharmaceutical compounds for the treatment of diabetes; pharmaceutical compounds for the treatment of Parkinson disease; pharmaceutical compounds for the treatment of multiple sclerosis; pharmaceutical compounds and substances for the prevention of cancer; pharmaceutical compounds and substances with analgesic properties; pharmaceutical compounds for the treatment of epilepsy, disorders of the intestines and of the sensory organs; pharmaceutical compounds for the prevention of disorders and diseases of the nervous system; pharmaceutical compounds and substances for the treatment of cancer and cardiovascular diseases; pharmaceutical compounds and substances for use in oncology; pharmaceutical products and substances for the treatment of gastrointestinal diseases; pharmaceutical compounds for the treatment of diseases of the central nervous system (CNS); biological preparations for treatment of neurological disorders; biological compounds for the treatment of cancer; biochemical compounds for the treatment of cancer and for pain treatment; biotechnological compounds for medical purpose, namely, bioactive pharmaceuticals for treatment of Alzheimer's and dementia; diagnostic biomarker reagents for medical purpose; bio-pharmaceuticals for the treatment of cancer
1 Chemical substances for the production of pharmaceuticals; esters of fatty acids for use in pharmaceuticals; preservatives for pharmaceutical compounds; antimicrobial preservatives for pharmaceutical compounds; chemicals for the preparation being manufacturing and production of pharmaceuticals; antioxidants for the production of pharmaceutical products; chemical compounds for the preparation being manufacturing of pharmaceutical products; esters being viscose chemicals for the production of pharmaceutical products; preservatives for use in the pharmaceutical industry; softening agents being chemical agents for manufacturing for use during the preparation of pharmaceuticals; chemical products for use in the pharmaceutical industry, namely, for use in pharmaceutical manufacturing; active chemical ingredients for the use during the preparation being manufacturing of pharmaceuticals; biochemical compounds for scientific purposes; biochemical products, namely polypeptides for in vitro research applications; biochemical products, namely, chemical reagents for in vitro genetic technology; reagents for use in scientific apparatus for chemical and biological analysis; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use
42 Development of pharmaceutical compounds and drugs; research and development of vaccine and drugs; pharmaceutical product development in relation to drugs; pharmaceutical research, research regarding pharmaceuticals; conducting of quality control tests on pharmaceutical products; medical and pharmaceutical research services; pharmaceutical research and development services; pharmaceutical research and development; development of pharmaceutical products; evaluation of results from quality control tests conducted on goods and services in relation to pharmaceutical products; consulting with regard to pharmacology; laboratory research services with regard to pharmaceuticals; research in the field of pharmaceuticals; consulting with regard to pharmaceutical research and development; scientific research in the field of pharmacy; pharmaceutical product evaluation, namely services for the evaluation of the therapeutic effects of pharmaceuticals; research and development services for the pharmaceutical industry; research and development in the field of pharmacy and biotechnology; information technology (IT) consultancy services for pharmaceutical industry and health sector; quality assessment in the nature of quality testing, analysis and evaluation with regard to research in the field of pharmacogenetics; biochemical research; biological research; biological analysis; biological research services; biological development services; biological laboratory services; biochemical analysis; biomedical research; biotechnological research; research regarding biotechnologies; biotechnological research services; scientific research regarding biology; biological research and analysis; research in the field of biotechnology; consulting in the field of biology; consulting in the field of biochemistry; research and development in the field of biochemistry; research and development services in the field of biotechnology
Feb 16, 2018
Application Filing Receipt Mailed
Feb 8, 2018
Sn Assigned For Sect 66a Appl From Ib
Feb 12, 2018
New Application Office Supplied Data Entered
Feb 12, 2018
Assigned To Examiner
Feb 21, 2018
Non-Final Action Written
Feb 22, 2018
Non-Final Action (Ib Refusal) Prepared For Review
Mar 2, 2018
Refusal Processed By Mpu
Mar 3, 2018
Non-Final Action Mailed - Refusal Sent To Ib
Mar 5, 2018
Non-Final Action Written
Mar 6, 2018
Non-Final Action Mailed
Mar 24, 2018
Refusal Processed By Ib
Jul 11, 2018
Notification Of Notice Of Publication E-Mailed
Jun 20, 2018
Teas Response To Office Action Received
Jun 20, 2018
Correspondence Received In Law Office
Jun 21, 2018
Teas/Email Correspondence Entered
Jun 21, 2018
Approved For Pub - Principal Register
Jul 5, 2018
Change Of Owner Received From Ib
Jul 11, 2018
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Oct 16, 2018
Registered-Principal Register
Jan 16, 2019
Final Disposition Notice Created, To Be Sent To Ib
Nov 19, 2022
New Representative At Ib Received
Jul 11, 2018
Notification Of Possible Opposition Sent To Ib
Jul 27, 2018
Notification Processed By Ib
Jul 31, 2018
Published For Opposition
Jul 31, 2018
Official Gazette Publication Confirmation E-Mailed
Jan 31, 2019
Final Disposition Processed
Jan 31, 2019
Final Disposition Notice Sent To Ib
Feb 22, 2019
Final Decision Transaction Processed By Ib
May 11, 2024
New Representative At Ib Received
Oct 16, 2023
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Trademark Alertz updated from USPTO on 2030-01-24
